Losmedicamentos deorigenbiotecnológico…
87
27. Vaklavas C, Forero-‐Torres A. Safety and efficacy of brentuximab vedotin in patients with
Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol
3
(4),
209-‐25(2012).
28. Stevens PL, OluwoleO, ReddyN. Advances andapplicationof radioimmunotherapy innon-‐
Hodgkin lymphoma. AmJBloodRes
2
(2), 86-‐97(2012).
29. Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-‐Hodgkin's
lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med
84
(4),
391-‐407(2011).
30. Weiss GR, GroshWW, Chianese-‐Bullock KA, Zhao Y, Liu H, Slingluff CL Jr, et al. Molecular
insights on the peripheral and intratumoral effects of systemic high-‐dose rIL-‐2
(aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res
17
(23), 7440-‐50(2011).
31. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikcevich DA, et al. Denileukin
diftitox in combination with rituximab for previously untreated follicular B-‐cell non-‐
Hodgkin's lymphoma. Leukemia
26
(5), 1046-‐52(2012).
32. Prince HM, Martin AG, Olsen EA, Fivenson DP, Duvic M. Denileukin diftitox for the
treatment of CD25 low-‐expression mycosis fungoides and Sézary syndrome. Leuk
Lymphoma
54
(1), 69-‐75(2013).
33. ChakrabortyA, TannenbaumS, Rordorf C, LowePJ, FlochD, GramH, et al. Pharmacokinetic
and pharmacodynamic properties of canakinumab, a human anti-‐interleukin-‐1β
monoclonal antibody. ClinPharmacokinet
51
(6), e1-‐18(2012).
34. Saghafi h, Rahbar K, Nobakht haghighi A, Qoreishi M , Safdari F. Efficacy of Anti-‐
Interleukin-‐2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute
RejectionAfterRenal Transplantation. Nephro-‐UrolMon
4
(2), 475-‐7(2012).
35. Chanvillard C, Jacolik RF, Infante-‐Duarte C, Nayak RC. The role of natural killer cells in
multiple sclerosis and their therapeutic implications. Front Immunol
4
, 63(2013).
36. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular
endothelial growth factor SNPs as predictive and prognostic markers for major solid
tumors.Mol CancerTher
8
(9), 2496-‐508(2009).
37. Akar EE, Oner V, Küçükerdönmez C, Aydın Akova Y. Comparison of subconjunctivally
injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal
neovascularization ina ratmodel. Int JOphthalmol
6
(2), 136-‐40(2013).
38. Li J, ZhangH, SunP, GuF, LiuZL. Bevacizumab vs ranibizumab for neovascular age-‐related
maculardegeneration inChinesepatients. Int JOphthalmol
6
(2), 169-‐73(2013).
39. Sun M, Shariat SF, Trinh QD, Meskawi M, Bianchi M, Hansen J, et al. An evidence-‐based
guide to the selection of sequential therapies inmetastatic renal cell carcinoma. Ther Adv
Urol
5
(2), 121-‐8(2013).
40. Matsumiya W, Honda S, Kusuhara S, Tsukahara Y, Negi A. Effectiveness of intravitreal
ranibizumab in exudative age-‐relatedmacular degeneration (AMD): comparison between
typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-‐up.
BMCOphthalmol
13
, 10(2013).
41. Sabour-‐Pickett S, Loughman J, Nolan JM, Stack J, Pesudovs K, Meagher KA, et al. Visual
performance in patients with neovascular age-‐related macular degeneration undergoing
treatmentwith intravitreal ranibizumab. JOphthalmol
2013
, 268438(2013).
42. ThomasM,Mousa SS,Mousa SA. Comparative effectiveness of aflibercept for the treatment
of patients with neovascular age-‐related macular degeneration. Clin Ophthalmol
7
, 495-‐
501(2013).
43. Ohr M, Kaiser PK. Aflibercept in wet age-‐related macular degeneration: a perspective
review. TherAdvChronicDis
3
(4), 153-‐61(2012).
44. SaeedMU, Gkaragkani E, Ali K. Emerging roles for antiangiogenesis factors inmanagement
of oculardisease. ClinOphthalmol
6
, 533-‐43(2013).
45. Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, et al. Efficacy and
Safety of AxitinibVersus Sorafenib inMetastatic Renal Cell Carcinoma: SubgroupAnalysis
of Japanese Patients from the Global Randomized Phase 3 AXIS Trial. Jpn J Clin Oncol
43
(6), 616-‐28(2013).
46. Busquets N, Carmona L, Surís X. [Systematic review: safety and efficacy of anti-‐TNF in
elderlypatients]. Reumatol Clin
7
(2), 104-‐12(2011).
47. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther
13
Suppl 1, S2
(2011).
